BVF Inc. IL Has $65.28 Million Stock Position in XOMA Royalty Corporation $XOMA

BVF Inc. IL lowered its holdings in XOMA Royalty Corporation (NASDAQ:XOMA) by 13.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,590,303 shares of the biotechnology company’s stock after selling 392,723 shares during the quarter. XOMA Royalty makes up about 2.3% of BVF Inc. IL’s investment portfolio, making the stock its 9th largest holding. BVF Inc. IL owned approximately 21.64% of XOMA Royalty worth $65,276,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its stake in XOMA Royalty by 13.9% in the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 543 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of XOMA Royalty in the 2nd quarter worth about $116,000. Deutsche Bank AG boosted its stake in shares of XOMA Royalty by 5,087.9% during the 1st quarter. Deutsche Bank AG now owns 6,433 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 6,309 shares in the last quarter. Rhumbline Advisers increased its position in shares of XOMA Royalty by 18.0% during the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after buying an additional 2,019 shares during the period. Finally, Nuveen LLC purchased a new position in shares of XOMA Royalty during the first quarter valued at about $286,000. 95.92% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

XOMA has been the subject of several research analyst reports. Benchmark restated a “buy” rating on shares of XOMA Royalty in a report on Friday. HC Wainwright dropped their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday. UBS Group set a $76.00 price objective on XOMA Royalty in a report on Tuesday. Zacks Research lowered XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 18th. Finally, Stifel Nicolaus set a $50.00 target price on shares of XOMA Royalty in a research report on Friday. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $60.60.

Insider Activity

In other news, CEO Owen Hughes purchased 100,000 shares of XOMA Royalty stock in a transaction that occurred on Thursday, December 4th. The stock was bought at an average price of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at approximately $2,555,100. The trade was a 5,000.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Thomas M. Burns sold 4,330 shares of the business’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the completion of the transaction, the chief financial officer owned 30,079 shares of the company’s stock, valued at approximately $1,082,543.21. The trade was a 12.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 9.10% of the stock is currently owned by insiders.

XOMA Royalty Trading Down 5.0%

NASDAQ XOMA opened at $25.22 on Friday. XOMA Royalty Corporation has a 12 month low of $18.35 and a 12 month high of $39.92. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The stock’s fifty day moving average price is $33.31 and its 200-day moving average price is $30.98. The stock has a market cap of $312.22 million, a P/E ratio of 34.08 and a beta of 0.94.

XOMA Royalty (NASDAQ:XOMA) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%.The company had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. As a group, equities analysts forecast that XOMA Royalty Corporation will post -1.41 EPS for the current fiscal year.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.